Member Info for ontarget

Net profit was -$2.3m

As a % of current net cash flow perhaps, but bear in mind that SHG has yet to report an annual net profit (certainly in the last few years), so in some ways its suprsing we get any dividend at all really.

For me the current 2% (@10p) is an ok dividend for now. I agreed with Eric's argument in the last Q&A that a dividend needs to be increased cautiously as it's never nice to have to reduce it again. In other words it needs to be sustainable.

What % yield would be a good dividend?

If you type the name for a female dog instead of ***** it will complete the URL

What about a 2% yield?

That was pretty low volume btw. Imagine what it could do if we get some real volume.

Interims and possibly other news next week

🤡

🤡

Good analysis of the RNS from one of our AI overlords:

"

hatfullofsky

31 Aug '23 - 10:51 - 2018 of 20190.002345 4 0

BTW I asked GPT to analyse the Phase 1b release, very interesting. Here's an extract :

Changes in Gene Expression: The fact that changes in gene expression were observed indicates that the drug, SFX-01, has effects at a genetic level. This is generally a positive outcome, as it suggests that the drug is interacting with the body's molecular processes in a way that leads to measurable changes.

Effects in Healthy Volunteers: The press release specifically mentions that these gene expression changes were observed "even in healthy volunteers." This is noteworthy because it suggests that the drug's effects on gene expression are not limited to individuals with specific conditions but are observable in a general population. This broader impact could have implications for the drug's potential therapeutic applications.

"

ISA->ISA transfer maybe. Last time I looked the limit is still £20k/year for new funds which obviously includes shares not already in an ISA.

Any comment on the £377k delayed buy?

Re: cash runway, from an RNS earlier this month

"As at 31 March 2023, Evgen had cash of £5m, without including any further milestone payments the current cash runway is to Q4 2024, with potential future milestones from partner Stalicla SA extending the cash runway into 2025."

Today's news as well as triggering a $0.5m milestone from Stalicla is a significant step on the way to much larger payments, with the next one $5m due on FDA IND receipt.

From today's RNS:

"We are sharing this report with our partner Stalicla SA as part of our collaboration and will be working with them on supporting regulatory submissions for Phase 2 trials in Autism Spectrum Disorder (ASD)."

And also, importantly from the Stalicla deal RNS:

"..with Stalicla funding all clinical development activities.

The forthcoming gioblastoma trial is also being funded by partners in the Netherlands where they have received grant funding, with more grant funding being sought.

So don't be taken in by the nonsense about a share placing being spread by a small number of trolls on here. They are well funded and have a series of milestones to come in the near term.

Excellent news and sounds like some very intriguing and exciting data regarding gene expression, surprised no mention of the $0.5m milestone payment now due although I guess they will RNS when they receive it from Stalicla.

Also didn't they say in the recent investormeet they would be putting the full results up for publication?

Flashgarden - correct

You need to zoom out a bit on your chart. The gold price is $300/oz higher (has been $400+/oz higher) than it was last November. Then compare to the shareprice - no different, even slightly lower than it was then.

Ooh there's that stench again

I think he implied in the previous presentation/q&a that the expansion was dependent on resource/reserve upgrades - no point doubling production and halving minelife I guess, they want to make sure it's sustainable and at the right grades.

CJ39, I hope this doesn't come across as patronising but you are crying over a loss of "over £3k" so you are obviously either fairly new to investing or this was only a very small part of your portfolio. I suspeect it wasn't the latter or you wouldn't be hanging around still posting on here, you'd be more concerned with the rest of your stocks.

So as a newbie to investing you are going to have to get used to things like timescales changing - it's what happens - nobody has lied to you but circumstances change especially when third parties are involved. It's also very common for shareprices to go down from the price you initially bought at before they go up again, the trick is not to sell at the bottom.

The mistake you're making is assuming they will burn through the cash at the same rate as last year. Evgen have told us consistently their runway is to the end of 2024, and beyond with milestone payments from Stalicla.

Last year they spent money on completing the new tablet forumulation, ramping up manufacturing, and running the P1b clinical trial - all those expenditures are done with so won't be repeated this year. The forthcoming ASD and Glioma clinical trials are fully funded by partners.